Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wvu Research Office

Neither a doctor nor a teaching hospital

Research payments

$552,055

77 payments

Through program year 2025, Wvu Research Office is reported as receiving $552,055 in research payments, across 77 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $47,285 4
2024 Research $79,183 22
2023 Research $66,921 11
2022 Research $95,374 13
2021 Research $125,097 21
2020 Research $138,195 6

Breakdown

Who paid Research payments · program years 2020–2025
  1. Regeneron Pharmaceuticals, Inc. $303,757 29 payments
  2. E.R. Squibb & Sons, L.L.C. $77,750 4 payments
  3. Acerta Pharma LLC $42,360 11 payments
  4. Celgene Corporation $41,246 4 payments
  5. AstraZeneca UK Limited $24,551 1 payment
  6. Ucb SA $20,488 2 payments
  7. Novo Nordisk AS $18,687 15 payments
  8. G1 Therapeutics, Inc. $10,000 1 payment
  9. AstraZeneca Pharmaceuticals LP $6,832 6 payments
  10. GlaxoSmithKline, LLC. $3,350 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity $184,169 9 payments
  2. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $59,892 13 payments
  3. A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $53,704 6 payments
  4. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $43,918 15 payments
  5. Deliver Insights on Safety in Hypertrophic Cardiomyopathy and Observe Endpoints in Real World (DISCOVER-HCM) $31,115 1 payment
  6. a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 $24,551 1 payment
  7. Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions $23,275 1 payment
  8. A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (DISCOVER-HCM) $23,040 1 payment
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $20,488 2 payments
  10. Nn9535-4801 $18,687 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record